DMSA vs DMPS: Which Oral Chelating Agent Fits Your Heavy Metal Profile?

At a Glance

Why the Comparison Matters Clinically

Heavy metal chelation is not a monolithic intervention. Choosing the wrong agent for the wrong metal can mean inadequate mobilisation, unnecessary mineral loss, or redistribution of metals into vulnerable tissues before they can be excreted. For a clinician ordering a chelation protocol, DMSA and DMPS are often presented as interchangeable — they are not.

Both belong to the dithiol family: they bind metals through two sulfhydryl (-SH) groups, forming stable complexes that are excreted predominantly via the kidneys. But their pharmacokinetic profiles, metal affinities, and tolerability differ enough that agent selection should follow the metal profile revealed on provoked urine or red blood cell (RBC) testing, not default preference or cost alone.

This guide covers the clinical decision framework I use in practice, where the choice between agents directly affects patient outcomes.

Mechanism: Same Family, Different Binding Profiles

DMSA and DMPS both work by coordinating metals through their dithiol groups, effectively displacing the metal from endogenous sulfhydryl-containing proteins (glutathione, metallothionein, enzyme active sites). The resulting metal-chelator complex is water-soluble and renally excreted — the same basic mechanism, but with different affinity constants for different metals.

DMSA Binding Affinities

DMSA’s structure — with carboxylate groups flanking the dithiol — gives it high affinity for divalent cations that favour oxygen-sulfur coordination. Lead (Pb²⁺) fits this profile exceptionally well, which is why DMSA received FDA approval (Chemet®) specifically for paediatric lead poisoning in 1991. It also chelates methylmercury (the organic form prevalent after fish consumption), making it the preferred agent when organic mercury predominates on testing.

DMSA is less efficient at mobilising inorganic mercury (the form released from dental amalgam vapour) and has limited affinity for arsenic in its inorganic trivalent form.

DMPS Binding Affinities

DMPS carries an additional sulfonate group, which alters its water solubility and metal-binding geometry. It has higher affinity for inorganic mercury, arsenic (both As³⁺ and As⁵⁺), and bismuth. In head-to-head provoked urine studies, DMPS consistently mobilises more inorganic mercury per dose than DMSA at equivalent dosing.

DMPS also has the advantage of an IV formulation used in European clinics, which produces a sharper, more predictable mobilisation peak — useful for diagnostic provocation or when rapid reduction in body burden is clinically indicated. In the United States, DMPS is available only through compounding pharmacies and is not FDA-approved.

Which Metals Respond Best to Each Agent

Lead Poisoning: DMSA First

For confirmed lead toxicity — occupational exposure, old paint, contaminated soil — DMSA is the standard of care in functional and conventional medicine alike. The FDA-approved paediatric protocol (10 mg/kg three times daily for 5 days, followed by 10 mg/kg twice daily for 14 days) has been replicated in adult practice. DMPS has some lead-mobilising capacity but has not demonstrated superiority over DMSA in controlled lead-chelation studies.

Mercury: Agent Selection Depends on Source

Mercury exposure comes in biologically distinct forms, and agent choice follows source:

• Methylmercury (fish, seafood): primarily stored in neural tissue and red blood cells. DMSA crosses the blood-brain barrier more readily than DMPS and is preferred for this form.
• Inorganic mercury (amalgam vapour, industrial): concentrated in kidneys and liver. DMPS mobilises this form more efficiently, with provocation studies showing 2–4× higher urinary mercury output per dose compared to DMSA in inorganic-dominant profiles.

Clinical pearl: when a patient’s provoked urine test shows a mixed mercury profile, I typically start with DMSA, reassess at 3–4 rounds, then transition to DMPS if redistribution appears to favour inorganic compartments on follow-up testing.

Arsenic: Both Work, DMPS Slightly Superior

Inorganic arsenic — from contaminated water, pressure-treated wood, or agricultural residue — responds to both agents. DMPS shows marginally superior mobilisation in controlled studies and is the preferred choice when arsenic is the primary concern. DMSA remains acceptable when DMPS is not accessible.

Nickel, Cadmium, and Other Metals

DMPS has demonstrated some efficacy for nickel and bismuth. Neither agent performs well for cadmium (which distributes heavily into the renal cortex and bone) — this is a limitation of the dithiol class generally. Cadmium chelation protocols typically use EDTA or combination approaches, with expectation management: cadmium is among the hardest metals to mobilise meaningfully.

Dosing Protocols in Clinical Practice

DMSA (Adult Protocol)

• Standard: 10 mg/kg orally every 8 hours for 5 days, off 9 days, repeat cycle
• Lower-intensity: 10 mg/kg every 8 hours for 3 days, off 11 days — used when tolerability is a concern or kidney function is borderline
• With meals: reduces GI side effects without significantly impairing absorption
• Maximum single dose: 500 mg in adults with normal renal function

DMPS (Adult Protocol — Oral)

• Standard: 100–300 mg every 8 hours for 3–5 days, off 9–11 days
• Lower-intensity: 100 mg twice daily continuously (used in some European protocols for chronic low-level exposure)
• IV form: 3–5 mg/kg IV over 20–30 minutes, monitored in clinic — produces a sharper mobilisation peak and is used diagnostically as well as therapeutically

Cycling Is Non-Negotiable

Both agents deplete essential minerals — particularly zinc and copper — during active chelation. A minimum of 9 days off between 5-day cycles allows the kidneys to recover and gives time for mineral repletion. Running consecutive cycles without breaks increases redistribution risk and depletes minerals faster than supplementation can replace them.

Mineral Depletion: Different Profiles, Same Imperative

Both DMSA and DMPS bind zinc and copper alongside target metals — this is unavoidable given the chemical similarity of essential and toxic metal coordination. However, the profiles differ slightly:

Clinical imperative: mineral testing (RBC zinc, serum copper, whole-blood selenium) should be performed before starting, after the first two cycles, and whenever the patient reports new fatigue, immune suppression, or taste disturbance — all early signals of zinc or copper depletion. Replenishment during the off-days is standard practice:

• Zinc bisglycinate 15–30 mg
• Copper glycinate 1–2 mg (ratio matters: too much zinc without copper causes secondary copper deficiency)
• Selenium 100–200 mcg (particularly important during DMPS protocols)

Tolerability and Side Effects

DMSA: The Sulphur Smell Problem

DMSA is metabolised to disulfides that are excreted via sweat, breath, and urine. The result is a pronounced sulphur odour that most patients find unpleasant and socially limiting. This is the most common reason for early discontinuation and should be addressed in the consultation: it is temporary, it indicates the drug is being metabolised correctly, and it fades within 24–48 hours of stopping a cycle.

Other DMSA side effects: nausea (particularly without food), loose stools, transient liver enzyme elevation (usually resolves), rash (rare — suspend if urticarial or involving mucosa).

DMPS: Generally Better GI Tolerance

DMPS does not produce the same sulphur odour as DMSA, which improves adherence. GI effects (nausea, bloating) can still occur but are typically milder with oral dosing. IV DMPS can cause transient hypotension, flushing, and — rarely — allergic reactions, which is why IV administration requires clinic monitoring and a minimum 20-minute infusion time.

Both agents are contraindicated in severe renal insufficiency (eGFR < 30 mL/min/1.73m²) — impaired excretion leads to metal-chelator complex accumulation and redistribution risk.

The Clinical Decision Framework

Here is the algorithm I use in practice after reviewing provoked urine heavy metal results:

Step 1 — Identify the dominant metal(s). A profile with primarily lead elevation: DMSA. Primarily inorganic mercury: DMPS. Mixed with organic mercury dominance: DMSA first. Arsenic: DMPS preferred.

Step 2 — Assess kidney function. Both agents require adequate renal excretion. If eGFR is 30–60, lower doses and extended off-cycles are mandatory. If < 30, neither agent should be used without specialist consultation.

Step 3 — Consider access and compounding. In the US, DMSA is commercially available (Chemet®) and can be compounded; DMPS requires compounding only. Compounding quality matters — verify your pharmacy follows USP 795/797 standards.

Step 4 — Baseline minerals before starting. Never begin a chelation protocol without knowing the patient’s baseline zinc, copper, and selenium status. Correcting pre-existing mineral deficiencies before the first cycle reduces the risk of exacerbating deficiency.

Step 5 — Monitor through cycles. Provoked urine retesting after 3–4 cycles confirms mobilisation is occurring and allows dose adjustment. Liver and kidney function (ALT, AST, creatinine, eGFR) should be checked at baseline and every 2–3 cycles.

Step 6 — Know when to stop. The endpoint is clinical improvement combined with normalising provoked urine outputs — not an arbitrary number of cycles. Some patients plateau after 4–6 cycles; others with high body burden require 12+ rounds. Continuing indefinitely without response data is not evidence-based.

What the Evidence Actually Shows

Randomised controlled trial evidence for chelation in non-acute heavy metal toxicity remains limited. Most of what guides practice comes from:

• DMSA in paediatric lead poisoning — the strongest evidence base: multiple RCTs confirming blood lead reduction, though long-term neurodevelopmental benefit is more variable
• TRIAL-II (TACT2) — EDTA-based, not dithiol, but the only large RCT of chelation in cardiovascular disease, showing modest benefit in diabetic patients with prior myocardial infarction
• Provocation studies — showing DMPS > DMSA for inorganic mercury mobilisation in comparative protocols
• Case series and observational data — the predominant evidence base for functional medicine applications of DMSA and DMPS

This evidence hierarchy should inform patient conversations: DMSA for lead is well-supported; DMPS for inorganic mercury is mechanistically sound with supportive but not RCT-level evidence for functional applications. Being transparent about this distinction is part of responsible clinical practice.

Related Articles

• Heavy Metal Chelation Protocol: A Clinical Overview
• Chelation Side Effects: What to Monitor and When to Pause
• Chelation Safety: Pre-Treatment Workup and Monitoring
• Heavy Metal Testing: Blood vs Provoked Urine
• Detox Protocols: A Functional Medicine Framework

References

1. Chisolm JJ Jr. “Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations.” J Toxicol Clin Toxicol. 2000;38(4):365-375.
2. Aposhian HV, Maiorino RM, Rivera M, et al. “Human studies with the chelating agents, DMPS and DMSA.” J Toxicol Clin Toxicol. 1992;30(4):505-528.
3. Bradberry SM, Vale JA. “Dimercaptosuccinic acid (succimer; DMSA) in inorganic lead poisoning.” Occup Environ Med. 2009;66(12):858.
4. Bernhoft RA. “Mercury toxicity and treatment: a review of the literature.” J Environ Public Health. 2012;2012:460508.
5. Bjørklund G, Dadar M, Mutter J, Aaseth J. “The toxicology of mercury: current research and emerging trends.” Environ Res. 2017;159:545-554.
6. Rooney JP. “The role of thiols, dithiols, nutritional factors and interacting ligands in the toxicology of mercury.” Toxicology. 2007;234(3):145-156.
7. Lamas GA, Goertz C, Boineau R, et al. “Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.” JAMA. 2013;309(12):1241-1250.